Cytochrome P450 3A5 (CYP3A5) is involved in the biotransformation of many orally administered drugs, some of which are dose optimized using therapeutic drug monitoring. The CYP3A5 gene exhibits variable inter-individual expression, which is related to a single-nucleotide polymorphism. Producers of the enzyme possess at least one CYP3A5Ã1 allele. Knowledge of patients' CYP3A5 genotype, in conjunction with therapeutic drug monitoring (TDM), may aid patient management. Real-time polymerase chain reaction (PCR) was used to genotype the A6986G mutation of the CYP3A5 gene. Specific primers were employed to generate a DNA product, co-amplified with two internal hybridization probes, using a LightCycler. DNA melt curve analysis readily identified the genotypes CYP3A5Ã1/Ã1, CYP3A5Ã1/Ã3 and CYP3A5Ã3/Ã3. Results were confirmed using DNA sequencing with 100% correlation. Genotypes were determined from 263 individuals and compared with the genotypes of a pseudogene CYP3AP1, which is in disequilibrium with CYP3A5. This is a rapid and reliable method for genotyping the CYP3A5 polymorphism which may be used as an important adjunct to the TDM service offered by laboratories to optimize drug prescription. Ann Clin Biochem 2005; 42: 376-381
Introduction
Therapeutic drug monitoring (TDM) is becoming an increasingly signi¢cant part of the work of hospital biochemistry laboratories. The oral bioavailability of a drug is a¡ected by a variety of factors, including absorption and metabolism. These factors in turn in£uence the process of optimizing drug dose. An equilibrium point poised between drug absorption, distribution and elimination determines the measured concentration of a drug. Thus, liver and intestinal metabolism of orally administered drugs has an important in£uence over drug analysis in blood. Many drugs dose optimized using TDM are metabolized by the enzyme cytochrome P4503A5 (CYP3A5), which is part of the cytochrome P450 3A subgroup. This group is the most abundant of the P450 family of enzymes in the liver, 1 and is also present in large amounts in the intestine, 2 contributing signi¢cantly to ¢rst-pass metabolism. 3 In adult humans, CYP3A4 and CYP3A5 are the most important with respect to enzymatic activity. 1, 4 CYP3A4 is thought to have evolved by a gene duplication event from CYP3A5. 5 The large variability in the production of the CYP3A enzymes that exists between individuals, which may be as much as 30-fold, 6 is attributed to heterogeneity conferred by di¡erences in the expression of CYP3A5 rather than CYP3A4. 7, 8 This inter-individual variability in expression is related to a single-nucleotide polymorphism within the gene encoding the CYP3A5 enzyme. 7, 9, 10 Homozygotes for the CYP3A5Ã3 polymorphism carry a G at position 6986 within the gene, and do not produce the enzyme CYP3A5. Expressers possess at least one CYP3A5Ã1 allele (A at position 6986). This polymorphic expression may contribute to the variations in rates of metabolism of CYP3A substrates, such as erythromycin and midazolam, 11 observed between individuals. There are di¡erences in the frequencies of this allele between racial groups: over 60% of African Americans possess the CYP3A5Ã1 allele compared with less than 10% of Caucasians. 7 Inter-racial di¡erences in drug dose requirements have been reported for immunosuppressants, 12 which may be attributed to these di¡erences in interracial frequencies of this polymorphism. 13, 14 In the context of immunosuppressants, the purpose of TDM is to aid in establishing the ¢ne balance between under-dosing leading to graft rejection and over-dosing leading to drug toxicity. This group of drugs is one of the most closely monitored categories of pharmaceuticals. Following allograft transplantation, maintaining blood concentrations of tacrolimus and cyclosporin within a narrow therapeutic range is essential for post-transplant patient management. A delay in achieving target blood concentrations has been associated with an increased rate of graft rejection. 15--17 In recent years, there has been considerable interest in correlating CYP3A5 genotype with the pharmacokinetics of the calcineurin inhibitors. 18, 19 A strong relationship has been described between tacrolimus dose-to-blood concentration ratios and patient genotype. 13, 20, 21 We have demonstrated that determining CYP3A5 genotype may be used to predict the tacrolimus dose requirement. Knowledge of patient genotype, in conjunction with TDM, may therefore aid perioperative patient care with regards to selecting the initial dose of an immunosuppressant, particularly for tacrolimus therapy. 20 In addition to its use in pharmacogenetics, there is considerable research interest in genetic analysis of the CYP3As, as this enzyme subgroup is involved in the metabolism of exogenous carcinogens and endogenous steroid hormones. Thus, CYP3A5 may be important in the study of steroidinduced cancer 22--24 as well as xenobiotic-related neoplastic diseases.
Published methods for genotyping CYP3A5 have relied on gene sequencing 7 or the use of 'mismatched' primers to generate restriction sites to enable restriction fragment length polymorphism (RFLP) analysis. 25--28 Sequencing can be expensive and requires specialized equipment to which many clinical chemistry laboratories do not have access. RFLP may be an alternative, but can be time-consuming. In the case of CYP3A5 analysis, the ampli¢cation, digestion and visualization methods are technically more involved than standard RFLP protocols. This is due to the absence of a naturally occurring splice site for known restriction endonucleases. In addition, the published methods generate fragment lengths of very similar sizes, 102 and 94 bp, 27 which are impossible to resolve using standard agarose electrophoresis protocols. To improve the resolution, most authors have employed 10% polyacrylamide gels. The equipment needed to run 170 Â200 Â1mm polyacrylamide gels is not normally available in clinical chemistry laboratories.
An alternative method of investigating genetic in£uences on drug dose requirements of substrates of the CYP3A enzymes has been to genotype the pseudogene CYP3AP1, 8 which shows results consistent with direct CYP3A5 genotyping. 13 A polymorphism of CYP3AP1, CYP3AP1Ã1 (CYP3AP1 A/G À44 ) has been shown to be associated with CYP3A expression. 5, 29 The CYP3AP1Ã1 genotype is strongly linked to CYP3A5Ã1. The pseudogene CYP3AP1 has a G4A point mutation at position --44, with CYP3AP1Ã1 having --44(G) and CYP3AP1Ã3 À44(A). 7 Therefore, a correlation would be expected to be observed between CYP3AP1Ã1 and CYP3A5Ã1 genotype frequencies in any given population.
We propose the use of real-time polymerase chain reaction (PCR) to genotype the A6986G mutation within intron 3 of the CYP3A5 gene. Our aim was to perform genotype analysis of CYP3A5 using the LightCycler. To validate the results obtained, we compared them with those obtained by DNA sequencing.
Method Materials
The FastStart DNA master Hybridisation Probe kit was obtained from Roche (Lewes, UK), custom-made oligonucleotides primers from Sigma-genosis (Poole, UK), custom-made probes from Tib Molbiol (Berlin, Germany), QIAmp DNA blood mini kit from Qiagen (Crawley, UK), and restriction endo-nucleases from New England Biolabs (Hitchin, UK).
Patient groups
Genotyping of CYP3A5 was performed using DNA extracted from whole blood taken from a total of 263 individuals. These subjects were categorized into six distinct ethnic groups; Middle Eastern, Indians (originating from Bangladesh, India and Pakistan), Blacks (originating fromWest Africa or the Caribbean), Caucasians, Nepalese and Ethiopians.
Ethical approval for all studies was obtained from the local research ethics committees of the appropriate institutes. These were: 
Genotyping
Qiagen Mini Blood DNA kits were used to extract DNA from stored EDTA anticoagulated wholeblood. Puri¢ed genomic DNA template 10--50 ng was ampli¢ed using capillary PCR on a LightCycler (Roche, Lewes, UK). Spe-ci¢c primers were employed to generate an ampli¢ed DNA product 356 bp in length using a FastStart DNA master Hybridisation Probe kit. Primer sequences were forward: 5 0 -ACTGCCCTTGCAGCATTTAG-3 0 ; and Ann Clin Biochem 2005; 42: 376-381 reverse: 5 0 -CATACCCCTAGTTGTACGAC-3 0 (GenBank Accession AC005020, position 22,675--23,030). Two hybridization probes were used, which hybridize with internal speci¢c sequences of the amplicon during the annealing phase of PCR. These are referred to as the Anchor probe: 5 0 -LC Red640-GTTTGGACCACAT TACCCTTCATC-3 0 -Phosphate, and Sensor probe: 5 0 -CT TTTGTCTTTCAATATCTCTTCCC-3 0 -£uorescein. The underlined base in the sensor probe indicates the polymorphic site. The reaction mixture consisted of 0.5 mmol of each primer and 0.2 mmol of each of the £uorescent probes. A 10 min pre-incubation phase at 951C was included to activate the Taq polymerase enzyme, followed by 45 cycles of denaturation (951C, 10 s), annealing (551C, 5 s) and extension (721C, 15 s). Melt curve analysis followed the ampli¢cation stage. This involved annealing at 451C for 15 s, followed by an increase in temperature at a rate of 0.11C/s, with continual £uorescence detection up to 671C. Light-Cycler Software was used to convert melting curves into melting peaks by plotting the negative derivatives of £uorescence against temperature (ÀdF/dT). Three control samples were included in each LightCycler run as positive controls, as well as two negative controls (water). Genomic DNA template (0.2--0.5 mg) was added to each reaction.
A small subset of samples was analysed using DNA sequencing. A selection of 21control samples, comprising 10 Black and 11 Indian subjects, were ampli¢ed using the same primers employed with the LightCycler and sequenced. PCR was performed using a conventional heating block thermal cycler (Hybaid, Ashford, UK) and sequencing was performed on an ABI 3100 Genetic Analyser (Applied Biosystems, Warrington, UK). These samples were analysed to con¢rm the genotypes obtained using the LightCycler.
CYP3A5 and CYP3AP1 genotype comparisons
All samples were genotyped for CYP3AP1 using PCR, followed by RFLP, including digestion with AciI restriction enzyme. This well-established method has been described previously. 8 
Results
Genotypes were readily identi¢ed by observing the characteristic DNA melting curves and melting peaks. Melting peaks of ampli¢ed DNA produced curves with distinctly characteristic shapes for the CYP3A5Ã1/Ã1, CYP3A5Ã1/Ã3 and CYP3A5Ã3/Ã3 genotypes. Melting peaks (t m ) for CYP3A5Ã1/Ã1 homozygotes were produced at approximately 551C, whereas melting peaks for CYP3A5Ã3/Ã3 homozygotes were at approximately 611C. Heterozygotes demonstrated two peaks, corresponding to 551C and 611C. Figure 1 shows representative melting curves and peaks for three control samples that were included within each PCR run. The genotypes of these samples were previously determined using DNA sequence analysis and selected as controls. There was 100% concordance between the genotypes of the 21 samples determined by sequencing and the genotypes determined by the LightCycler method. The CYP3A5 allele frequencies were in Hardy-Weinberg equilibrium (w 2 ¼2.5, P ¼ 0.12). Comparisons between genotypes for the CYP3A5 and the pseudogene CYP3AP1 showed a high degree of concordance between the frequency of homozygotes and heterozygotes for the overall sample group (w 2 ¼1.1, P ¼ 0.59). Results are summarized in Table1. This degree of agreement di¡ered between di¡erent racial groups.
Discussion
Capillary PCR using the LightCycler is a reliable, convenient and simple method for genotyping CYP3A5 polymorphisms. It showed excellent correlation with genotype determination by DNA sequencing. The strength of agreement between the allele frequencies of CYP3A5Ã1 and CYP3AP1Ã1 varied between the di¡erent racial groups (Table 1) in a manner that is re£ected in previously published reports. 30 As with CYP3A5Ã1, the CYP3AP1Ã1 genotype has been shown to be associated with CYP3A expression 5 and it has therefore been suggested that CYP3AP1genotyping may be considered a strong indicator of high CYP3A metabolic activity. 29 The ethnic group with the largest number of CYPA5 expressers were the Blacks of West African origin (86.2%) and the lowest were the Caucasians (16.2%).
A direct association between the CYP3A5 genotype and tacrolimus dose requirement has been reported. 13, 25, 31, 32 Information on factors a¡ecting dose requirements are important, as the rapid attainment of target blood concentrations of both cyclosporine and tacrolimus following transplantation has been associated with a lower rate of acute rejection. 15--17 We have previously demonstrated that patients genetically predicted to be CYP3A5 expressers experience a significant delay in achieving target blood concentrations of tacrolimus, in spite of dose adjustments made using TDM. Genotyping for the CYP3A5Ã1/Ã3 polymorphism could identify patients who will require an initial tacrolimus dose up to twice that of the normal dose.
The method outlined here has many advantages over other published methods. 7, 9, 10 The main issue limiting the widespread adoption of this approach in the clinical chemistry laboratory is the cost of the equipment. However, genetic testing and molecular diagnostics are becoming an increasing part of the clinical chemistry laboratory's repertoire. Several capillary-based PCR methods have recently been reported within the chemical pathology ¢eld, including tests for factor V Leiden mutation, 33 the prothrombin variant, 34 the haemochromatosis gene mutations 35 and apolipoprotein E (Apo E). 36 Roche Diagnostics, the manufacturer of the LightCycler, have produced a kit for Apo E genotyping speci¢cally marketed for use in chemical pathology laboratories. Based on the amount of coverage in the literature of topics such as molecular diagnostics, and in particular rapid methods of genetic testing, it may be the case that automated or semi-automated systems will soon become a staple of the standard clinical chemistry laboratory. Many of the older molecular biology techniques are inappropriate for hospital laboratories, as the routine detection of mutations of pathological interest requires accurate, rapid and reliable methods. The advent of small-scale real time-PCR analysis, and the interest shown by some of the large diagnostic kit manufacturers, make the routine rapid processing of samples for genetic analysis feasible. Although individual variability in drug response is a¡ected by many factors, genotyping may be used to predict extensive, intermediate and poor metabolizers of drugs. The LightCycler method of genotyping CYP3A5 could be an important adjunct to the TDM service o¡ered by laboratories to optimize drug-dosing regimens.
